CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions

Hsiang Wei Kuo, Shu Chih Liu, Hsiao Hui Tsou, Sheng Wen Liu, Keh Ming Lin, Shao Chun Lu, Mei Chun Hsiao, Chin Fu Hsiao, Chia Yih Liu, Chia Hui Chen, Mong Liang Lu, Winston W. Shen, Hwa Sheng Tang, Shen Ing Liu, Liang Huey Chang, Hsiao Yu Wu, Yao Sheng Chang, Teng Kuang Yeh, Andrew Ch Chen, Yu Li Liu

研究成果: 雜誌貢獻文章

15 引文 斯高帕斯(Scopus)

摘要

Aim: The liver CYP1A2 enzyme may metabolize antidepressant escitalopram (S-CIT) to S-desmethylcitalopram (S-DCIT) and S-didesmethylcitalopram (S-DDCIT). This study tested whether genetic polymorphisms in the CYP1A2 gene are associated with the treatment responses to S-CIT. Materials & methods: Ten SNPs in CYP1A2 were selected and genotyped in 158 patients under S-CIT treatment. The serum levels of S-CIT and its metabolites were measured by HPLC. Results:CYP1A2 SNPs rs2069521, rs2069526, rs4646425 and rs4646427 are significantly associated with the metabolic ratios of S-DDCIT/S-DCIT (p = 0.002, 0.018, 0.008 and 0.004, respectively) at week 2 of treatment. Carriers of the allele types associated with higher S-DDCIT/S-DCIT ratios had more severe side effects. Conclusion: These results suggest that genetic variants in CYP1A2 may be indicators for S-CIT metabolism and that the fast metabolizers may experience more severe adverse reactions in the early stages of S-CIT treatment. Original submitted 27 December 2012; Revision submitted 15 May 201.

原文英語
頁(從 - 到)1191-1201
頁數11
期刊Pharmacogenomics
14
發行號10
DOIs
出版狀態已發佈 - 2013
對外發佈Yes

    指紋

ASJC Scopus subject areas

  • Pharmacology
  • Genetics
  • Molecular Medicine
  • Medicine(all)

引用此

Kuo, H. W., Liu, S. C., Tsou, H. H., Liu, S. W., Lin, K. M., Lu, S. C., Hsiao, M. C., Hsiao, C. F., Liu, C. Y., Chen, C. H., Lu, M. L., Shen, W. W., Tang, H. S., Liu, S. I., Chang, L. H., Wu, H. Y., Chang, Y. S., Yeh, T. K., Chen, A. C., & Liu, Y. L. (2013). CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions. Pharmacogenomics, 14(10), 1191-1201. https://doi.org/10.2217/pgs.13.105